Jay Schmelter (RiverVest)

River­Vest off to the races with $275M to in­vest in ear­ly-stage biotech

River­Vest Ven­ture Part­ners has closed its largest fund yet, with $275 mil­lion to in­ject in­to ear­ly-stage drug and med­ical de­vice de­vel­op­ers.

The fifth fund …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.